Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 330

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 330
---
 Company has sold no shares of Common Stock to Arena under the Arena ELOC during the three months ended March 31, 2025 and 2024. F-21 Sale of Pre-funded Warrants and Common Stock On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551shares of its common stock, par value $ 0.0001per share (the “Common Stock”) or common stock equivalents in lieu thereof (the Company sold 15,000shares of its common stock and 112,551pre-funded warrants) ; and (ii) common warrants to purchase up to 127,551shares of common stock (the “Warrants”), at a combined public offering price of $ 39.20per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company and each investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received net proceeds of approximately $ 4.2million, which is net of offering costs and fees of $ 839,004. During the three months ended March 31, 2025, 15,000shares of common stock were purchased upon the closing of the Offering and 91,214shares were issued in connection with the exercise of pre-funded warrants, totaling 106,214shares of its common stock issued of the aggregate amount of 127,551Common Stock shares sold. As of March 31, 2025, 21,337pre-funded warrants remain exercisable. The Warrants have an exercise price of $ 39.20per share, are immediately exercisable upon stockholder approval and have a term of exercise equal to five yearsfollowing the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price. In connection with the Offering, on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Alliance Global Partners (“A.G.P.”), as the exclusive placement agent in connection